Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCCR in Prader-Willi Syndrome (C602)
NCT03714373Phase 3Completed
- Sponsor
- Soleno Therapeutics
- Start
- Oct 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in Prader-Willi syndrome (PWS) (3 arms), sponsored by Soleno Therapeutics. Primary endpoints: Incidence and severity of adverse events up to 4 years and Hyperphagia Questionnaire for Clinical Trials Total Score at 16 weeks. Started Oct 2018; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT03714373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714373.